Biochemical recurrence-free survival and pathological outcomes after radical prostatectomy for high-risk prostate cancer-Reference-Cited by-同舟云学术

Biochemical recurrence-free survival and pathological outcomes after radical prostatectomy for high-risk prostate cancer

Published:2016-06-08 Issue:1 Volume:16 Page:
ISSN:1471-2490
Container-title:BMC Urology
language:en
Short-container-title:BMC Urol

Author:

Beauval Jean-Baptiste,Roumiguié Mathieu,Filleron Thomas,Benoit Thibaut,de la Taille Alexandre,Malavaud Bernard,Salomon Laurent,Soulié Michel,Ploussard Guillaume

Publisher

Springer Science and Business Media LLC

Subject

Urology,Reproductive Medicine,General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12894-016-0146-6.pdf

Reference19 articles.

1. Heidenreich A, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59:61–71.

2. Bosetti C, Bertuccio P, Chatenoud L, Negri E, La Vecchia C, Levi F. Trends in mortality from urologic cancers in Europe, 1970–2008. Eur Urol. 2011;60:1–15.

3. D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–74.

4. Garzotto M, Hung AY. Contemporary management of high-risk localized prostate cancer. Curr Urol Rep. 2010;11:159–64.

5. Gerber GS, Thisted RA, Chodak GW, et al. Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur Urol. 1997;32:385–90.

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pelvic Lymph Node Dissection: A Comparison Among Extraperitoneal Single-port and Transperitoneal Multiport Radical Prostatectomy—A Single-center Experience;European Urology Open Science;2024-09

2. A transcriptomic signature for prostate cancer relapse prediction identified from the differentially expressed genes between TP53 mutant and wild-type tumors;Scientific Reports;2022-06-22

3. Effect of pelvic lymph node dissection and its extent on oncological outcomes in intermediate‐risk prostate cancer patients: A multicenter study of the Turkish Uro‐oncology Association;The Prostate;2022-02-21

4. Immunoexpression of HSPA9 and CUL2 in prostatic tissue and adenocarcinoma;Annals of Diagnostic Pathology;2022-02

5. Prognostic value of FUS immunoexpression for Gleason patterns and prostatic adenocarcinoma progression;Annals of Diagnostic Pathology;2021-06